The effects of omeprazole and famotidine on mucin and PGE2 release in the rat stomach

التفاصيل البيبلوغرافية
العنوان: The effects of omeprazole and famotidine on mucin and PGE2 release in the rat stomach
المؤلفون: C. R. Boland, Kenji Yoshimura, S. G. Delbarre, Eugene R. Kraus
المصدر: Alimentary Pharmacology & Therapeutics. 10:111-117
بيانات النشر: Wiley, 1996.
سنة النشر: 1996
مصطلحات موضوعية: medicine.medical_specialty, Hepatology, business.industry, medicine.drug_class, medicine.medical_treatment, Stomach, Mucin, Gastroenterology, Proton-pump inhibitor, Pharmacology, Famotidine, Endocrinology, medicine.anatomical_structure, Histamine H2 receptor, Internal medicine, medicine, Pharmacology (medical), Prostaglandin E2, business, Omeprazole, Prostaglandin E, medicine.drug
الوصف: SUMMARY Background: Gastric antisecretory agents may inhibit the synthesis or secretion of gastric mucin during acid suppression, which would interfere with mucosal protection and limit the efficacy of the agents. Methods: Rats were dosed with famotidine, omeprazole, or buffer control for 4 weeks. Mucin synthesis, mucin histochemistry, mucin carbohydrate composition and prostaglandin E, (PGE,) release were measured during and after drug treatment. Results : PGE, release was maximally inhibited after 2 weeks of omeprazole or 4 weeks of famotidine. Total glycoprotein synthesis was inhibited at all times by omeprazole, but only after the cessation of dosing with famotidine. Sulphated glycoprotein synthesis was inhibited by both drugs at 2 weeks. PGE,release and sulphated glycoprotein synthesis were restored to control values or more by the 5th day after the end of dosing, at which time total glycoprotein synthesis was significantly suppressed in both groups. Histologically, a reduction of PAS-positive surface mucus was observed after 2 weeks of dosing in both groups. Both famotidine and omeprazole reduced the sialic acid content during and after treatment. Conclusions : These results suggest that Iong-term antisecretory therapy also affects the production of factors involved in primary gastric mucosal defence, which should be considered in the assessment of response to treatment in clinical trials.
تدمد: 0269-2813
DOI: 10.1111/j.1365-2036.1996.tb00184.x
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::e47a9d78de644551f16c3edc8826246a
https://doi.org/10.1111/j.1365-2036.1996.tb00184.x
Rights: OPEN
رقم الانضمام: edsair.doi...........e47a9d78de644551f16c3edc8826246a
قاعدة البيانات: OpenAIRE
الوصف
تدمد:02692813
DOI:10.1111/j.1365-2036.1996.tb00184.x